A Phase 2 interventional study of D-2570 and D-2570 Placebo in Active Systemic Lupus Erythematosus, sponsored by InventisBio Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-24.
Sponsored by InventisBio Co., Ltd · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 266 studies in Lupus Erythematosus, Systemic with a site in China — 168 open to participants now, 191 under way, 22 of them phase 3. Lupus Erythematosus, Systemic · China.
Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, this one is the 62nd largest by planned enrollment of the 245 interventional ones that give a count, is one of 56 that started in 2026, is one of 33 in phase 2, reaches primary completion later than 158 of the 190 other live ones, and was the 216th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →168 of the 266 studies in Lupus Erythematosus, Systemic with a site in China are open now. Recruiting first, the newest first:
Genentech, Inc. · Sites in China, Australia, Brazil and 3 more countries
Ages 18–75
Antengene Biologics Limited · Sites in China
Ages 18+
AstraZeneca · Sites in China, United States, Argentina and 32 more countries
Ages 5–80
AstraZeneca · Sites in China
Ages 18–70
Peking Union Medical College Hospital · Sites in China
Ages 6–18
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
266 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 128 · Phase 2 56 · Phase 3 36 · Phase 4 16
First in 2006; this study’s year is marked. 56 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 36 across the 245 interventional studies, 180 across the 21 observational. Of the 54 that completed or were terminated, 25 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
133 of 266 have an industry lead sponsor. The 10 most frequent:
InventisBio Co., Ltd is the lead sponsor of 34 studies on the registry; 11 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
InventisBio Co., Ltd has 1 study filed under Lupus Erythematosus, Systemic — fewer than ten, so there is no comparison to draw.
58 of the studies in Lupus Erythematosus, Systemic with a site in China that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05843643Phase 3AbbVieProgram to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | 2027-03 |
| NCT05639114Phase 3Novartis PharmaceuticalsPhase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) | 2027-03-26 |
| NCT05126277Phase 3Novartis PharmaceuticalsSafety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | 2027-09-21 |
| NCT07657793Phase 3Chinese SLE Treatment And Research GroupSirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia | 2027-09-30 |
Add all 58 to your calendar (.ics) → With an account.
Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy and safety of D-2570 in the treatment of active systemic lupus erythematosus.
Subjects who sign the informed consent form will enter the screening period, during which their eligibility will be assessed according to the inclusion and exclusion criteria. Eligible participants who meet the inclusion criteria and do not meet any exclusion criteria will be randomized. Participants will then be assigned to one of the following groups: Group A, Group B, Group C, or the placebo group. They will proceed to the treatment period, during which they will take the corresponding investigational product once daily for 48 consecutive weeks. After completing the treatment, subjects will undergo safety follow-up. Throughout the treatment period, both investigators and subjects will remain blinded. During the study, participants will be required to provide pharmacokinetic and pharmacodynamic blood samples at the time points specified in the trial protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: D-2570 · Drug: D-2570 Placebo
Drug: D-2570 · Drug: D-2570 Placebo
Drug: D-2570
Drug: D-2570 Placebo
Participants will be assigned to one of the following groups: Group A, Group B, Group C, or the placebo control group.
D-2570 Placebo
Proportion of subjects achieving the Systemic Lupus Erythematosus Responder Index-4 (SRI-4) at Week 32
Time frame: Week 32
Proportion of subjects achieving SRI-4 at Weeks 4, 12, 24, and 48
Time frame: Weeks 4, 12, 24, and 48
Proportion of subjects achieving Systemic Lupus Erythematosus Responder Index-6 (SRI-6) at Weeks 4, 12, 24, 32, and 48
Time frame: Weeks 4, 12, 24, 32, and 48
Improvement rate in the Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) score from baseline at Weeks 4, 12, 24, 32, and 48
Time frame: Weeks 4, 12, 24, 32, and 48
Proportion of subjects with a Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity score improvement of ≥50% from baseline at Weeks 4, 12, 24, 32, and 48, among those with a baseline CLASI activity score of ≥10
Time frame: Weeks 4, 12, 24, 32, and 48
Proportion of subjects with ≥6 active (tender or swollen) joints at baseline who achieve a reduction of ≥50% in active (tender or swollen) joint count from baseline at Weeks 4, 12, 24, 32, and 48
Time frame: Weeks 4, 12, 24, 32, and 48
Proportion of subjects achieving the British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) at Weeks 4, 12, 24, 32, and 48
Time frame: Weeks 4, 12, 24, 32, and 48
Proportion of subjects achieving Lupus Low Disease Activity State (LLDAS) at Weeks 4, 12, 24, 32, and 48
Time frame: Weeks 4, 12, 24, 32, and 48
Proportion of subjects with a prednisone dose of ≤5.0 mg/day or a reduction of ≥25% from baseline dose during Weeks 44-48
Time frame: Weeks 44-48
Changes from baseline of anti-double-stranded DNA (dsDNA) antibody
Time frame: From enrollment to the end of treatment at 48 weeks
blood drug concentration of D-2570
Time frame: From enrollment to the end of treatment at 48 weeks
Incidence of adverse events rate based on NCI CTCAE V5.0
Time frame: From enrollment to 52 weeks
Changes from baseline of complement (C3) levels
Time frame: From enrollment to the end of treatment at 48 weeks
Changes from baseline of complement C4 levels
Time frame: From enrollment to the end of treatment at 48 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Aug 2028, 30 months after the start.
Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's planned 30 months is close to that.
Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: D-2570
Lupus Erythematosus, Systemic →